Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 15/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 15/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17446926 | 0.87 | PDE3B (0.76) | PDE3BPDE3AGPR119SMN1; SMN2 | |
| SCHEMBL17446925 | 0.87 | PDE3B (0.76) | PDE3BPDE3AGPR119SMN1; SMN2 | |
| SCHEMBL16156958 | 0.86 | PDE3B (0.78) | PDE3BPDE3AGPR119 | |
| SCHEMBL17446952 | 0.84 | PDE3B (0.73) | PDE3BPDE3AGPR119MAPTSMN1; SMN2 | |
| SCHEMBL17446940 | 0.84 | PDE3B (0.73) | PDE3BPDE3AGPR119MAPTSMN1; SMN2 | |
| SCHEMBL17446931 | 0.81 | PDE3B (0.70) | PDE3BPDE3AGPR119MAPT | |
| SCHEMBL17446933 | 0.78 | PDE3B (0.54) | PDE3BPDE3AGPR119MAPT | |
| SCHEMBL22288560 | 0.74 | PDE3B (0.50) | PDE3BPDE3AGPR119GAAMAPT | |
| SCHEMBL22288916 | 0.74 | GPR119 (0.53) | PDE3BPDE3AGPR119GAAMAPT | |
| SCHEMBL16157201 | 0.74 | PDE3B (0.78) | PDE3BPDE3AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890127-B2 | Compounds and compositions for the treatment of cancer | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TP53, RB1, CDK4 | PDE3B 2667/4885PDE3A 2661/4885GPR119 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.